Shunsuke Eguchi
Shunsuke Eguchi has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Kazuma Iekushi
Medical Affairs Division, Novartis Pharma K.K.
3 shared publications - Daisuke Yarimizu
Medical Affairs, Novartis Pharma K.K. Tokyo Japan
2 shared publications - Hiroki Murayama
Medical Division, Cardio-Metabolic Medical Franchise Department Novartis Pharma K.K Tokyo Japan
2 shared publications - Hiromi Rakugi
Department of Geriatric and General Medicine The University of Osaka Graduate School of Medicine Suita Japan
2 shared publications - Kazuomi Kario
Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Tochigi, Japan.
2 shared publications Kinsuke Tsuda
2 shared publications
Latest Publications
- Open Access
- 1 January 2025
- Published by Japan Society for Occupational Health in Environmental and Occupational Health Practice
- Vol. 7 (1) , 2024-0017
Attitude change to secondary health examination using social nudging through a spouse
Objectives: Hypertension and dyslipidemia are major risk factors of cardiovascular diseases. Nevertheless, many people do not consider these risk factors important, even if they are noted during their annual health checkups and left untreated for a long time. Here, we report a novel nudge method to encourage people who had these risk factors and examine the resultant changes in the willingness to undergo secondary health examinations. Methods: Employees of Novartis Pharma K.K. and its affiliated companies who had elevated blood pressure and/or lipid levels during annual health checkups were allocated to either the social nudge group (postcards were sent to their spouses) or the control group (postcards were sent to themselves) after confirming their agreement to receive postcards in order to encourage them to take secondary health examination. A web-based survey via email was conducted before and after sending the postcards to understand the willingness to undergo secondary health examinations. Results: Regarding the willingness to undergo the secondary health examinations, a significant difference was observed in the social nudge group (n=58) before (12.1%) and after (46.6%) the postcard was sent (p<0.0001), and no significant difference was observed in the control group (n=9, p=1.0000). The proportion of employees who underwent secondary health examinations did not increase significantly in either group. Conclusions: This study suggested that a social nudge via spouse has a possibility of increasing the willingness to undergo secondary health examinations at low cost. To increase the proportion of undergoing it, combinations with other nudges might be necessary.
- 1 January 2025
- Published by Japan Society for Occupational Health in Environmental and Occupational Health Practice
- Vol. 7 (1) , 2024-0017
Open AccessAttitude change to secondary health examination using social nudging through a spouse
Objectives: Hypertension and dyslipidemia are major risk factors of cardiovascular diseases. Nevertheless, many people do not consider these risk factors important, even if they are noted during their annual health checkups and left untreated for a long time. Here, we report a novel nudge method to encourage people who had these risk factors and examine the resultant changes in the willingness to undergo secondary health examinations. Methods: Employees of Novartis Pharma K.K. and its affiliated companies who had elevated blood pressure and/or lipid levels during annual health checkups were allocated to either the social nudge group (postcards were sent to their spouses) or the control group (postcards were sent to themselves) after confirming their agreement to receive postcards in order to encourage them to take secondary health examination. A web-based survey via email was conducted before and after sending the postcards to understand the willingness to undergo secondary health examinations. Results: Regarding the willingness to undergo the secondary health examinations, a significant difference was observed in the social nudge group (n=58) before (12.1%) and after (46.6%) the postcard was sent (p<0.0001), and no significant difference was observed in the control group (n=9, p=1.0000). The proportion of employees who underwent secondary health examinations did not increase significantly in either group. Conclusions: This study suggested that a social nudge via spouse has a possibility of increasing the willingness to undergo secondary health examinations at low cost. To increase the proportion of undergoing it, combinations with other nudges might be necessary.
- Open Access
- 4 December 2024
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 27 (1)
Efficacy and Safety of Sacubitril/Valsartan Versus Amlodipine in Japanese Patients With Essential Hypertension: A Randomized, Multicenter, Open‐Label, Noninferiority Study (PARASOL Study)
Sacubitril/valsartan, an angiotensin receptor‐neprilysin inhibitor, has demonstrated a superior blood pressure‐lowering effect compared with renin‐angiotensin system inhibitors in several clinical trials. However, there has been no available evidence on the comparison between sacubitril/valsartan and calcium channel blockers (CCBs), a well‐established class of antihypertensive drugs.In this open‐label, multicenter study, we aimed to demonstrate the efficacy and safety of sacubitril/valsartan versus amlodipine, one of the most widely used CCBs, after 8 weeks of treatment. A total of 359 Japanese patients with essential hypertension (office systolic blood pressure [SBP] ≥ 150 to < 180 mmHg), aged 18–79, were randomly assigned to receive either once‐daily sacubitril/valsartan 200 mg or once‐daily amlodipine 5 mg in a 1:1 allocation ratio. The primary endpoint was the noninferiority of sacubitril/valsartan compared with amlodipine in mean change in 24‐h SBP from baseline to Week 8, followed by a significance test as a secondary endpoint analysis. The mean change in 24‐h SBP in sacubitril/valsartan was noninferior to that in amlodipine (between‐treatment difference −0.62 mmHg [95% confidential interval: −3.23 to 1.98; p = 0.003 for noninferiority; independent t‐test with noninferiority margin 3.0 mmHg]), with no significant difference observed (p = 0.637). There was no significant difference in the incidence of adverse events (AEs). These results suggested that the blood pressure‐lowering effect of sacubitril/valsartan is comparable to that of amlodipine, with no marked differences in tolerability between the two groups. Sacubitril/valsartan, a potent antihypertensive drug comparable to amlodipine, is expected to improve blood pressure control in clinical practice.
- 4 December 2024
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 27 (1)
Open AccessEfficacy and Safety of Sacubitril/Valsartan Versus Amlodipine in Japanese Patients With Essential Hypertension: A Randomized, Multicenter, Open‐Label, Noninferiority Study (PARASOL Study)
Sacubitril/valsartan, an angiotensin receptor‐neprilysin inhibitor, has demonstrated a superior blood pressure‐lowering effect compared with renin‐angiotensin system inhibitors in several clinical trials. However, there has been no available evidence on the comparison between sacubitril/valsartan and calcium channel blockers (CCBs), a well‐established class of antihypertensive drugs.In this open‐label, multicenter study, we aimed to demonstrate the efficacy and safety of sacubitril/valsartan versus amlodipine, one of the most widely used CCBs, after 8 weeks of treatment. A total of 359 Japanese patients with essential hypertension (office systolic blood pressure [SBP] ≥ 150 to < 180 mmHg), aged 18–79, were randomly assigned to receive either once‐daily sacubitril/valsartan 200 mg or once‐daily amlodipine 5 mg in a 1:1 allocation ratio. The primary endpoint was the noninferiority of sacubitril/valsartan compared with amlodipine in mean change in 24‐h SBP from baseline to Week 8, followed by a significance test as a secondary endpoint analysis. The mean change in 24‐h SBP in sacubitril/valsartan was noninferior to that in amlodipine (between‐treatment difference −0.62 mmHg [95% confidential interval: −3.23 to 1.98; p = 0.003 for noninferiority; independent t‐test with noninferiority margin 3.0 mmHg]), with no significant difference observed (p = 0.637). There was no significant difference in the incidence of adverse events (AEs). These results suggested that the blood pressure‐lowering effect of sacubitril/valsartan is comparable to that of amlodipine, with no marked differences in tolerability between the two groups. Sacubitril/valsartan, a potent antihypertensive drug comparable to amlodipine, is expected to improve blood pressure control in clinical practice.
- Open Access
- 18 April 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (8)
Twenty‐Four‐Hour Blood Pressure‐Lowering Efficacy of Sacubitril/Valsartan Versus Olmesartan in Japanese Patients With Essential Hypertension Based on Nocturnal Blood Pressure Dipping Status: A Post Hoc Analysis of Data From a Randomized, Double‐Blind Multicenter Study
Background: Nighttime blood pressure (BP) and an abnormal nocturnal BP dipping profile are important cardiovascular risk factors in patients with hypertension. This post hoc analysis investigated the effects of sacubitril/valsartan on 24‐hour BP in patients with mild‐to‐moderate hypertension and in patient subgroups based on nocturnal BP dipping status. Methods and Results: Data from a randomized clinical trial comparing the BP‐lowering effects of 8 weeks of treatment with sacubitril/valsartan (200 or 400 mg/d) and olmesartan (20 mg/d) in Japanese patients with mild‐to‐moderate hypertension were analyzed. The primary end point was change in 24‐hour, daytime, and nighttime BP in patient subgroups based on nocturnal BP dipping status (dipper, nondipper). Six hundred thirty‐two patients with baseline and follow‐up ambulatory BP data were included. Both sacubitril/valsartan dosages reduced 24‐hour, daytime, and nighttime systolic BP, and 24‐hour and daytime diastolic BP, to a significantly greater extent than olmesartan in the dipper and nondipper groups. However, between‐group differences in nighttime systolic BP were more significant in the nondipper group (difference [95% CI] for sacubitril/valsartan 200 and 400 mg/d versus olmesartan 20 mg/d: –4.6 [95% CI, −7.3 to −1.8] and −6.8 [95% CI, −9.5 to −4.1] mm Hg, respectively; P P <0.001). Between‐group differences in the BP control rate were greatest in the nondipper subgroup (systolic BP control rate of 34.4% and 42.6% with sacubitril/valsartan 200 and 400 mg/d versus 23.1% with olmesartan 20 mg/d). Conclusions: This analysis highlights the value of sacubitril/valsartan therapy in patients with a nondipper profile of nocturnal BP and confirms this agent's potent 24‐hour BP‐lowering effect in Japanese populations with hypertension. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01599104.
- 18 April 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (8)
Open AccessTwenty‐Four‐Hour Blood Pressure‐Lowering Efficacy of Sacubitril/Valsartan Versus Olmesartan in Japanese Patients With Essential Hypertension Based on Nocturnal Blood Pressure Dipping Status: A Post Hoc Analysis of Data From a Randomized, Double‐Blind Multicenter Study
Background: Nighttime blood pressure (BP) and an abnormal nocturnal BP dipping profile are important cardiovascular risk factors in patients with hypertension. This post hoc analysis investigated the effects of sacubitril/valsartan on 24‐hour BP in patients with mild‐to‐moderate hypertension and in patient subgroups based on nocturnal BP dipping status. Methods and Results: Data from a randomized clinical trial comparing the BP‐lowering effects of 8 weeks of treatment with sacubitril/valsartan (200 or 400 mg/d) and olmesartan (20 mg/d) in Japanese patients with mild‐to‐moderate hypertension were analyzed. The primary end point was change in 24‐hour, daytime, and nighttime BP in patient subgroups based on nocturnal BP dipping status (dipper, nondipper). Six hundred thirty‐two patients with baseline and follow‐up ambulatory BP data were included. Both sacubitril/valsartan dosages reduced 24‐hour, daytime, and nighttime systolic BP, and 24‐hour and daytime diastolic BP, to a significantly greater extent than olmesartan in the dipper and nondipper groups. However, between‐group differences in nighttime systolic BP were more significant in the nondipper group (difference [95% CI] for sacubitril/valsartan 200 and 400 mg/d versus olmesartan 20 mg/d: –4.6 [95% CI, −7.3 to −1.8] and −6.8 [95% CI, −9.5 to −4.1] mm Hg, respectively; P P <0.001). Between‐group differences in the BP control rate were greatest in the nondipper subgroup (systolic BP control rate of 34.4% and 42.6% with sacubitril/valsartan 200 and 400 mg/d versus 23.1% with olmesartan 20 mg/d). Conclusions: This analysis highlights the value of sacubitril/valsartan therapy in patients with a nondipper profile of nocturnal BP and confirms this agent's potent 24‐hour BP‐lowering effect in Japanese populations with hypertension. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01599104.
- Open Access
- 26 June 2022
- Published by Springer Nature in Drugs - Real World Outcomes
- Vol. 9 (3) , 377-389
Burden of Repeated Hospitalizations on Patients with Heart Failure: An Analysis of Administrative and Claims Data in Japan
Background Repeated hospitalization is a predictor of outcomes in heart failure, indicating the presence of symptoms, a deteriorated condition at pre-admission, and worsened prognosis. Objectives The current database study aimed to understand the clinical and economic burden of repeated hospitalizations among patients with heart failure in Japan. The effect of repeated hospitalizations on the subsequent in-hospital mortality was the primary objective; economic burden of heart failure after discharge was investigated as a secondary outcome. Methods Between 2013 and 2018, administrative claims and discharge summary data of patients aged ≥ 20 years and diagnosed with heart failure were obtained from a Diagnosis Procedure Combination database maintained by Medical Data Vision. Hospitalization, mortality, and economic burden data were analyzed. Results This study included 49,094 patients. The mean length of the first hospital stay was 22.9 days. The in-hospital mortality rate was approximately 10%, with one to five repeated hospitalizations. The time interval between repeated hospitalizations for heart failure decreased with an increasing number of hospitalizations. In-hospital mortality did not increase even with an increasing number of hospitalizations. The mean heart failure-related healthcare cost per patient was ¥564,281 ± 990,447 (US$5178 ± 9,088), 67.3% of which was hospitalization costs. Among hospitalization costs, other costs were high, mainly for basic hospitalization fees (71.7%; ¥233,146/person-year). Conclusions Repeated hospitalization did not increase in-hospital mortality; however, it may shorten the intervals between heart failure-related hospitalizations, potentially caused by deterioration of the patient’s condition, and increase the clinical and economic burden on patients.
- 26 June 2022
- Published by Springer Nature in Drugs - Real World Outcomes
- Vol. 9 (3) , 377-389
Open AccessBurden of Repeated Hospitalizations on Patients with Heart Failure: An Analysis of Administrative and Claims Data in Japan
Background Repeated hospitalization is a predictor of outcomes in heart failure, indicating the presence of symptoms, a deteriorated condition at pre-admission, and worsened prognosis. Objectives The current database study aimed to understand the clinical and economic burden of repeated hospitalizations among patients with heart failure in Japan. The effect of repeated hospitalizations on the subsequent in-hospital mortality was the primary objective; economic burden of heart failure after discharge was investigated as a secondary outcome. Methods Between 2013 and 2018, administrative claims and discharge summary data of patients aged ≥ 20 years and diagnosed with heart failure were obtained from a Diagnosis Procedure Combination database maintained by Medical Data Vision. Hospitalization, mortality, and economic burden data were analyzed. Results This study included 49,094 patients. The mean length of the first hospital stay was 22.9 days. The in-hospital mortality rate was approximately 10%, with one to five repeated hospitalizations. The time interval between repeated hospitalizations for heart failure decreased with an increasing number of hospitalizations. In-hospital mortality did not increase even with an increasing number of hospitalizations. The mean heart failure-related healthcare cost per patient was ¥564,281 ± 990,447 (US$5178 ± 9,088), 67.3% of which was hospitalization costs. Among hospitalization costs, other costs were high, mainly for basic hospitalization fees (71.7%; ¥233,146/person-year). Conclusions Repeated hospitalization did not increase in-hospital mortality; however, it may shorten the intervals between heart failure-related hospitalizations, potentially caused by deterioration of the patient’s condition, and increase the clinical and economic burden on patients.
- Open Access
- 8 July 2019
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 2 (3)
Cover Image
- 8 July 2019
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 2 (3)
Open AccessCover Image
- Open Access
- 16 May 2019
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 2 (3) , e00068
Relationship between diet/exercise and pharmacotherapy to enhance the GLP‐1 levels in type 2 diabetes
The rapid rise in the prevalence of type 2 diabetes mellitus (T2DM) poses a huge healthcare burden across the world. Although there are several antihyperglycaemic agents (AHAs) available including addition of new drug classes to the treatment algorithm, more than 50% of patients with T2DM do not achieve glycaemic targets, suggesting an urgent need for treatment strategies focusing on prevention and progression of T2DM and its long‐term complications. Lifestyle changes including implementation of healthy diet and physical activity are cornerstones for the management of T2DM. The positive effects of diet and exercise on incretin hormones such as glucagon‐like peptide‐1 (GLP‐1) have been reported. We hypothesize an IDEP concept (Interaction between Diet/Exercise and Pharmacotherapy) aimed at modifying the diet and lifestyle, along with pharmacotherapy to enhance the GLP‐1 levels, would result in good glycaemic control in patients with T2DM. Consuming protein‐rich food, avoiding saturated fatty acids and making small changes in eating habits such as eating slowly with longer mastication time can have a positive impact on the GLP‐1 secretion and insulin levels. Further the type of physical activity (aerobic/resistance training), intensity of exercise, duration, time and frequency of exercise have shown to improve GLP‐1 levels. Apart from AHAs, a few antihypertensive drugs and lipid‐lowering drugs have also shown to increase endogenous GLP‐1 levels, however, due to quick degradation of GLP‐1 by dipeptidyl peptidase‐4 (DPP‐4) enzyme, treatment with DPP‐4 inhibitors would protect GLP‐1 from degradation and prolong its activity. Thus, IDEP concept can be a promising treatment strategy, which positively influences the GLP‐1 levels and provide additive benefits in terms of improving metabolic parameters in patients with T2DM and slowing the progression of T2DM and its associated complications.
- 16 May 2019
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 2 (3) , e00068
Open AccessRelationship between diet/exercise and pharmacotherapy to enhance the GLP‐1 levels in type 2 diabetes
The rapid rise in the prevalence of type 2 diabetes mellitus (T2DM) poses a huge healthcare burden across the world. Although there are several antihyperglycaemic agents (AHAs) available including addition of new drug classes to the treatment algorithm, more than 50% of patients with T2DM do not achieve glycaemic targets, suggesting an urgent need for treatment strategies focusing on prevention and progression of T2DM and its long‐term complications. Lifestyle changes including implementation of healthy diet and physical activity are cornerstones for the management of T2DM. The positive effects of diet and exercise on incretin hormones such as glucagon‐like peptide‐1 (GLP‐1) have been reported. We hypothesize an IDEP concept (Interaction between Diet/Exercise and Pharmacotherapy) aimed at modifying the diet and lifestyle, along with pharmacotherapy to enhance the GLP‐1 levels, would result in good glycaemic control in patients with T2DM. Consuming protein‐rich food, avoiding saturated fatty acids and making small changes in eating habits such as eating slowly with longer mastication time can have a positive impact on the GLP‐1 secretion and insulin levels. Further the type of physical activity (aerobic/resistance training), intensity of exercise, duration, time and frequency of exercise have shown to improve GLP‐1 levels. Apart from AHAs, a few antihypertensive drugs and lipid‐lowering drugs have also shown to increase endogenous GLP‐1 levels, however, due to quick degradation of GLP‐1 by dipeptidyl peptidase‐4 (DPP‐4) enzyme, treatment with DPP‐4 inhibitors would protect GLP‐1 from degradation and prolong its activity. Thus, IDEP concept can be a promising treatment strategy, which positively influences the GLP‐1 levels and provide additive benefits in terms of improving metabolic parameters in patients with T2DM and slowing the progression of T2DM and its associated complications.